Full Breakdown
GSK to Acquire Nuvalent in $10.6 Billion Deal to Bolster Lung-Cancer Portfolio
6/10/2026, 4:04:41 AM
Deal Overview
GlaxoSmithKline (GSK) announced a cash transaction to acquire U.S. biotech Nuvalent for $10.6 billion, valuing each Nuvalent share at $124—a 40 % premium to the prior close and 26 % above the 30-day volume-weighted average. After accounting for Nuvalent’s cash balance, the net outlay is estimated at $9.4 billion. The acquisition will be financed primarily with new and existing debt and is slated to close in the third quarter of 2026.
Background & Strategic Context
The purchase follows Luke Miels’s appointment as GSK CEO in January 2026 and reflects a strategic shift toward oncology. GSK seeks to offset an anticipated revenue dip from the 2028 expiry of its flagship HIV drug dolutegravir and to meet a corporate target of £40 billion in annual sales by 2031. Oncology sales rose 43 % to just under £2 billion in 2025, representing 6 % of total revenue, but still trail rival AstraZeneca’s 44 % share.
Key Assets and Pipeline
Nuvalent contributes two late-stage non-small-cell lung-cancer (NSCLC) candidates:
- zidesamtinib – a ROS1-targeted tyrosine-kinase inhibitor, under FDA review with a decision expected 18 September 2026.
- neladalkib – an ALK-selective inhibitor designed to retain activity after resistance to earlier ALK drugs, with an FDA decision slated for 27 November 2026.
Both drugs hold Breakthrough Therapy and Orphan Drug designations. An early-stage HER2 inhibitor (NVL-330) is in Phase 1 trials. Bank of America analysts estimate combined peak sales of $3-4 billion, while Jefferies projects $5-7 billion at full market penetration.
Timeline of Transaction
- Jan 2026: Luke Miels becomes GSK CEO.
- 9 June 2026: Acquisition announced; Nuvalent shares jump ~38 % in pre-market trading, GSK shares dip ~3 % in London.
- Q3 2026: Expected closing of the deal.
- 18 Sept 2026: FDA decision on zidesamtinib.
- 27 Nov 2026: FDA decision on neladalkib.
- 2027 onward: Anticipated contribution to GSK revenue and earnings.
Financial Data & Market Reaction
The $10.6 billion figure appears in most reports; one source cites $11 billion, creating a minor valuation discrepancy. The transaction represents GSK’s largest acquisition in over a decade and more than double the size of its 2025 purchase of Tesaro. Analysts expect a low-single-digit dilution to core earnings per share between 2026 and 2028, with profitability contributions beginning in 2027.
Why It Matters
The deal gives GSK immediate access to ROS1- and ALK-positive NSCLC therapies that aim to improve durability, reduce resistance, and better penetrate the brain—areas where existing drugs such as Xalkori, Pfizer’s Lorbrena, and Roche’s Alecensa have limitations. Successful approvals would help GSK meet its growth targets and diversify revenue ahead of the HIV patent cliff.
Official Statements & Responses
- Luke Miels, GSK CEO: The acquisition “provides immediate new sales growth opportunities” and creates “a platform in lung cancer that can be expanded with our Ris-Rez ADC.”
- James Porter, Nuvalent CEO: GSK’s “proven track record, infrastructure, and expertise will support the successful commercialization of our programs and accelerate our broader discovery pipeline.”
GSK also affirmed that the deal will not affect its investment-grade credit rating, dividend policy, or 2026 guidance.
Criticism & Opposition
Stifel analyst Laura Prendergast noted that the timing surprised investors, who had expected a post-launch bid when commercial outlooks would be clearer. Analysts also warned that neladalkib will face competition from Pfizer’s Lorbrena and Roche’s Alecensa, potentially limiting market share.
Conflicting Reports & Gaps
- Deal value: $10.6 billion (majority) vs. $11 billion (single source).
- Profit timeline: Some statements cite revenue impact from 2027, while others reference core earnings per share improvements only by 2029.
- Regulatory outcomes: FDA decisions for both drugs remain pending, leaving launch timing uncertain.
Verbatim Quotes
- “Today’s acquisition is a multi-product deal, consistent with our approach to acquire assets that have clinically proven targets and meaningfully address an efficacy and/or tolerability gap,” — Luke Miels, CEO, GSK
- “We’re excited that GSK has recognized the significant value these programs can offer patients and shares our vision for practice-changing innovation,” — James Porter, CEO, Nuvalent
- “The acquisition provides GSK with immediate new sales growth opportunities, improving profit contributions from 2027, and a platform in lung cancer…” — Luke Miels, CEO, GSK
- “However, she added that the timing of the deal came as a surprise to some investors, who expected bidders to wait until after launch, when the commercial outlook was clearer and data for both drugs in first-line treatment was nearer or available.” — Laura Prendergast, Analyst, Stifel
What’s Next
GSK will await FDA rulings in September and November 2026. If approved, zidesamtinib and neladalkib could launch later in the year, feeding into GSK’s broader oncology agenda that includes the Ris-Rez antibody-drug conjugate and a $12 billion R&D alliance with China’s Hengrui Pharma. Successful integration aims to help GSK achieve its £40 billion sales goal by 2031.
